Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 1000 shares trading hands. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The company has a market capitalization of C$13.74 million, a PE ratio of -0.63 and a beta of 0.69. The company’s 50 day simple moving average is C$0.06 and its 200 day simple moving average is C$0.06.
Resverlogix (TSE:RVX – Get Free Report) last announced its quarterly earnings results on Monday, April 1st. The biotechnology company reported C($0.01) EPS for the quarter. On average, equities analysts forecast that Resverlogix Corp. will post -0.22 EPS for the current year.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- Retail Stocks Investing, Explained
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- Find and Profitably Trade Stocks at 52-Week Lows
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- EV Stocks and How to Profit from Them
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
